

15 July 2010

Lifeline Scientific, Inc.
(“Lifeline” or the “Company”)

Admission of shares and TVR

Itasca, Illinois, US, 15 July 2010 - Lifeline Scientific, the medical technology company focused on the worldwide commercialisation of its LifePort Kidney Transporter, a product designed to address the global challenge of human donor organ shortages, announces that the Company has today made application to AIM for the admission of 19,495 Regulation S certificated common shares of \$0.01 each as the result of an exercise of warrants at a price of £1.65. Admission is expected to occur on 21 July 2010.

Following admission Lifeline will have 17,531,359 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 17,531,359.

Following admission the above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify the Company of their interests in, or change to their interests in, Lifeline Scientific, Inc. under the FSA's Disclosure and Transparency Rules.

Following admission, 7,036,594 common shares remain subject to Regulation S restrictions and are held in certificated form only. These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.

The remaining 10,494,765 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.

Enquiries:

Lifeline Scientific, Inc.	+ 1 847 824 2420
David Kravitz, CEO	
Seymour Pierce	+44 (0)20 7107 8000
Mark Percy	
Financial Dynamics	+44 (0)20 7831 3113
Ben Brewerton	